(TSX: MSL) (NASDAQ: MSLI) has closed a deal with Belgian drugmaker UCB to acquire rights to Elantan, Isoket and Deponit in Europe and select other markets, the company said.
(TSX: MSL) (NASDAQ: MSLI) has entered into an agreement with Belgian drugmaker UCB to acquire rights to Elantan, Isoket and Deponit in Europe and select other markets, the company said.
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.